Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Cash & Equivalents (2016 - 2026)

Agios Pharmaceuticals (AGIO) has disclosed Cash & Equivalents for 15 consecutive years, with $113.6 million as the latest value for Q1 2026.

  • For Q1 2026, Cash & Equivalents rose 43.86% year-over-year to $113.6 million; the TTM value through Mar 2026 reached $113.6 million, up 43.86%, while the annual FY2025 figure was $89.1 million, 16.9% up from the prior year.
  • Cash & Equivalents hit $113.6 million in Q1 2026 for Agios Pharmaceuticals, up from $89.1 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $253.7 million in Q3 2024 and bottomed at $64.3 million in Q3 2023.
  • Average Cash & Equivalents over 5 years is $103.5 million, with a median of $88.5 million recorded in 2022.
  • Year-over-year, Cash & Equivalents tumbled 95.76% in 2022 and then skyrocketed 294.4% in 2024.
  • Agios Pharmaceuticals' Cash & Equivalents stood at $139.3 million in 2022, then plummeted by 36.66% to $88.2 million in 2023, then dropped by 13.56% to $76.2 million in 2024, then increased by 16.9% to $89.1 million in 2025, then grew by 27.45% to $113.6 million in 2026.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $113.6 million, $89.1 million, and $92.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.